IPX

IPX's government-backed IBAS award and prototype orders materially de‑risk near-term scaling and give the company a runway to prove commercial throughput, but the stock is now a conditional, event-driven bet: investors should require visible, quarter-over-quarter evidence of repeatable production, rising government/commercial revenues, and narrowing negative FCF before adding exposure. Watch two binary triggers closely—(1) demonstrable ramp to contracted throughput (and at-or-below projected unit costs) within the next 2–4 quarters, and (2) resolution or material clarification of securities probes and guidance to avoid dilutive financings—because failure on either will likely compress valuation further.